Avanos (NYSE: AVNS) CEO Pacitti receives new option and RSU grants

Rhea-AI Filing Summary

Avanos Medical Chief Executive Officer David Pacitti received new equity awards in the form of stock options and restricted share units. On March 13, 2026, he was granted options to purchase 239,354 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.

He also received 101,341 time-based restricted share units, each equivalent to one share of Common Stock, increasing his direct Common Stock holdings to 343,388 shares after the grant. These awards vest over three years, with portions scheduled to vest on March 13, 2027, March 13, 2028, and March 13, 2029, aligning his compensation with the company’s long-term performance.

Insights

Executive compensation analyst

CEO Pacitti received sizable option and RSU grants that increase his long-term equity exposure without immediate share sales.

The filing shows David Pacitti, Chief Executive Officer of Avanos Medical, receiving an option grant for 239,354 shares at an exercise price of $13.69 and 101,341 time-based restricted share units on March 13, 2026. Both are compensation-related awards, not open-market purchases.

The RSUs vest in tranches through 2029, and the options expire in 2036, creating long-dated performance alignment. There are no reported sales or tax-withholding dispositions in this filing, and post-transaction direct holdings of Common Stock total 343,388 shares. Overall, this appears to be a routine, structured equity grant for a CEO rather than a directional trading signal.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Pacitti David

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	239,354	$0.00	--
Grant/Award	Common Stock	101,341	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 239,354 shares (Direct); Common Stock — 343,388 shares (Direct)

Footnotes (1)

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Key Figures

Option grant size: 239,354 shares Option exercise price: $13.69 per share Option expiration: March 13, 2036 +2 more

5 metrics

Option grant size 239,354 shares Employee stock option grant on March 13, 2026

Option exercise price $13.69 per share Exercise price for CEO stock options

Option expiration March 13, 2036 Expiration date of employee stock options

RSU grant size 101,341 units Time-based restricted share units granted March 13, 2026

Shares held after grant 343,388 shares Direct Common Stock holdings after RSU award

Key Terms

time-based restricted share units, TRSUs, Long Term Incentive Plan, Employee Stock Option (right to buy), +1 more

5 terms

time-based restricted share units financial

"Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan"

TRSUs financial

"Each TRSU is the economic equivalent of one share of Common Stock"

Long Term Incentive Plan financial

"awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended"

A long term incentive plan is a company program that awards executives and key employees bonuses—often in stock, options, or cash—only if the business meets multi-year performance goals. It links management pay to company results—like tying a coach’s bonus to a team’s multi-season record—so investors monitor it for how leaders are motivated, potential share dilution, and signals about the company’s long-term priorities.

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacitti David

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GEORGIA 30004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		101,341(1)	A	$0	343,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		239,354		(2)	03/13/2036	Common Stock	239,354	$0	239,354	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

This Form 4/A is being filed to correct a Form 4/A filed on April 1, 2026 that erroneously added to the number of stock options issued to the Reporting Person on March 13, 2026 pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended. The number of stock options originally reported in the Form 4 filed on March 17, 2026 was correct.

	/s/ John Hurley, as attorney-in-fact for David Pacitti	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)